A further analysis showed median time-averaged reductions during 150 days of follow up exceeded 80% in 300 mg and 600 mg treatment groups. Zerlasiran was well tolerated with no serious safety issues identified. The Company remains on-track to report topline data from the multiple dose portion of the APOLLO program in the fourth quarter of this year.